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Introduction
The novel coronavirus disease 2019 (COVID-19) 
pandemic has rapidly spread in many countries around the 
world. As of June 18, 2020, more than 8 million people have 
been infected, with near to 440 000 deaths.1 COVID-19 
is affecting adults more than children specially those 
younger than 15 years of age. The three main symptoms 
of the infection are cough, shortness of breath and fever. 
Some other symptoms include headache, malaise and sore 
throat which are less common. Most of these symptoms 
are presentations of respiratory tract infection. However, 
there have been reports about symptoms which overlap 
with cardiovascular symptoms.2
Some of these patients have underlying cardiovascular 
diseases, which affects their disease progression 
and outcome, but others might also present with 
cardiovascular manifestations. They might either present 
with cardiovascular findings or develop cardiovascular 
complication.2,3 But this is not the first time for 
cardiovascular presentations of coronavirus. There have 
been some studies reporting these presentations by 
previously known strains of the coronavirus family. Severe 
acute respiratory syndrome (SARS) caused by SARS-
associated coronavirus has presented itself in many ways 
during the previous years.4-7
Studying the previous presentations of coronavirus 
family and the recent cardiovascular manifestations 
of COVID-19 can help in predicting possible future 
challenges and taking measures to tackle these issues. The 
aim of this systematic review was to gather cardiovascular 
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Manifestations caused by coronavirus family have presented it in many ways during the previous 
years. The aim of this systematic review was to gather all possible cardiovascular manifestations of the 
coronavirus family in the literature. Adhering to Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines, we searched PubMed, Scopus, Web of Science, Cochrane and 
ProQuest which were updated on May 1, 2020 for the last time. Regarding to the novelty and speed 
of publications on COVID-19, we searched Google Scholar and also references of included studies 
and review articles in the systematic search results were searched manually. The searched keywords 
were the combination of the following MeSH terms: “COVID-19”, “SARS”, “MERS” and “cardiovascular 
presentation”. The systematic review was registered with ID CRD42020180736 in International 
Prospective Register of Systematic Reviews (PROSPERO). After screening, 28 original articles and ten 
case studies (five case reports and five case series) were included. Most of the studies were focused 
on COVID-19 (20 original articles and five case studies) while the only studies about Middle East 
Respiratory Syndrome (MERS) was a case report. Almost all the cardiovascular presentations and 
complications including acute cardiac injury, arrhythmias and the thrombotic complications were 
more prevalent in COVID-19 than severe acute respiratory syndrome (SARS) and MERS. The cardiac 
injury was the most common cardiovascular presentation and complication in COVID-19 whereas 
thrombotic complications were commonly reported in SARS. The cardiac injury was the predictor 
of disease severity and mortality in both COVID-19 and SARS. Coronavirus 2019 may present with 
cardiovascular manifestations and complications in signs and symptoms, laboratory data and other 
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presentations of the coronavirus diseases including SARS, 
MERS and COVID-19 in the literature.
Material and Methods
Search strategy
PubMed, Scopus, Web of Science, Cochrane and 
ProQuest were searched systematically based on the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guideline and updated on May 
1, 2020 for the last time.8 Regarding to the novelty and 
speed of publications on COVID-19, we searched Google 
Scholar and also references of included studies and review 
articles in the systematic search results were searched 
manually. The searched keywords were the combination of 
the following MeSH terms: “COVID-19”, “SARS”, “MERS” 
and “cardiovascular presentation”. The systematic review 
was registered with ID CRD42020180736 in PROSPERO 
International prospective register of systematic reviews 
and the complete search strategy is available online. On 
May 6, 2020, we added another researcher who helped in 
carrying on the systematic review to the PROSPERO. We 
also added the search strategy for all databases that were 
used. There were no changes in the protocol during the 
review.
Study selection
Interventional or descriptive studies on cardiovascular 
manifestations or complications of confirmed cases of 
three Coronaviruses including COVID-19, MERS and 
SARS were included in the study. There was no limitation 
on the year of publication or age of the study population. 
However, only articles in English Language were included. 
Case reports and letters were not excluded. Animal studies, 
reviews and guidelines were considered as exclusion 
criteria. Title, abstract and full text of search results were 
screened by two investigators independently and in any 
case of disagreement, the third senior investigator was 
asked to make the decision after discussion about the 
issue.
Our outcomes of interest were the various 
cardiovascular specific presentations, the cardiovascular 
related laboratory and imaging findings, complications 
and outcomes in SARS, MERS and COVID-19.
Data extraction
For each included study, the type of Coronavirus infection, 
year and country of publication, and the name of the first 
author were summarized into a table. Reported cardiac 
presentations and complications with their prevalence in 
the study population if available, were gathered and their 
impact on outcomes of the disease were added to the table. 
The data extraction was performed by two investigators 
independently and the third investigator was asked to 
participate in the case of disagreement.
Quality assessment
For quality assessment, the Quality Assessment Tool for 
Studies with Diverse Designs (QATSDD) was used.9 Two 
investigators assessed each study independently and the 
third investigator was asked to make the decision in the case 
of disagreement. The quality assessment was only done for 
original articles and case studies were not assessed. Also, 
quality assessment was not done for excluded articles. 
The QATSDD consists of 16 questions that 2 of them are 
for qualitative studies only. For each question there is a 
possible score 0 to 3 that makes the highest possible score 
to be 42. After scoring each question, the overall score for 
each article was calculated and then the percentage of the 
42 was determined.
Results
After screening, 28 original articles and 10 case studies (5 
case reports and 5 case series) were included. Most of the 
studies were focused on COVID-19 (20 original articles 
and four case studies), and 12 articles (eight original and 
four case studies) were focused on SARS. While there were 
only two studies about MERS. The PRISMA flow diagram 
is shown in Figure 1. Quality of most 20 studies was more 
than 70%. The range of the percent of quality was 40% to 
88%. Original studies were retrospective in 22 articles and 
China was the origin of most of the articles.
The original articles and case reports are summarized in 
Table 1 and Table 2 respectively.
Original studies
Cardiovascular presentation
Ten COVID-19 manuscripts reported cardiac injury as 
the cardiovascular presentation of patients. However, 
only three manuscripts reported elevated creatine kinase 
levels in SARS patients without a significant increase 
in the MB isoform. Seven (one original study and six 
case studies) manuscripts reported electrocardiography 
changes and arrhythmias such as ventricular fibrillation 
and tachycardia as the presentation of patients infected 
with coronaviruses.
Cardiovascular complication
From the COVID-19 manuscripts, eight studies reported 
cardiac injury as a complication of the infection with 
incidence of 7.4%-77% according to the included 
patients’ disease severity. Heart failure was reported as the 
complication in four manuscripts with an incidence of 1%-
49%. Regarding arrhythmias, only two studies reported 
them as the complication of COVID-19 infection with an 
incidence of 10.4%-60%. Studies related to SARS infection 
reported ischemic strokes, deep vein thrombosis (DVT), 
pulmonary embolism and cardiomegaly as cardiovascular 
complications of the infection.
Cardiovascular outcome
Most studies reported cardiac injury as predictors of 
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disease severity and mortality. Some studies indicated that 
patients who had cardiac injury needed more intensive 
care unit hospitalization. Acute myocardial infarction, 
arrhythmias and heart failure were regarded as the cause 
of death in some patients.
Case studies
Table 2 summarizes the different cases reported with 
COVID-19, SARS and MERS infection and their 
cardiovascular presentations, complications or outcomes. 
Overall, the cases included patients experiencing 
cardiogenic shock, myocarditis, ischemic stroke, 
myocardial infarction, DVT and pulmonary embolism.
Discussion
As experience with COVID-19 grows, the management 
of cardiovascular problems has become one of the 
most important challenges in caring process of these 
patients. While the world is in the grip of the COVID-19 
pandemics, we took a look back at SARS and MERS and 
tried to show differences and similarities between the three 
kind of Coronavirus infection in terms of cardiovascular 
manifestations and outcomes.
A similar pathogenesis has been suggested for three 
viruses. It has also been shown that the presence of 
cardiovascular comorbidities is accompanied with more 
severe illness and mortality in all three cases of Coronavirus 
infection.1-43 However, although the pandemics of 
COVID-19 has not ended, besides its reproductive number 
which is significantly higher in COVID-19 than SARS 
and MERS and their similarities such as more infection 
in adult and men, it seems that COVID19 compared to 
the other Coronavirus infections is more possible to 
manifest with a cardiovascular sign and symptom. 3,4,10,41-
42,44-45 Interestingly, although it has been suggested that the 
three viruses may cause myocardial damage in victims, 
compared to SARS and COVID-19, the data regarding the 
cardiovascular manifestations of MERS were scarce and 
we could find limited reports regarding the presentation 
of MERS with cardiovascular manifestation.40-41,46
The acute cardiac injury or a myocarditis like syndrome 
which would be the most common cardiac involvement 
during Coronavirus infections has been more prevalently 
reported in those with COVID-19. The development 
of cardiovascular complications later in the course of 
the disease has also been reported more frequently in 
COVID-19.2,3,10,13-14,47-48
As far as we searched, the acute cardiac injury was 
not reported as initial presentation of SARS. Regarding 
the MERS, Alhogbani et al reported a 60-year-old man 
with fever, respiratory symptoms, left ventricular systolic 
dysfunction, pericardial effusion and elevated cardiac 
biomarkers with final diagnosis of acute myocarditis 
based on the cardiac MR findings.40 In a case series by 
Al-Abdallat et al a fatal case of MERS with pericarditis, 
pericardial and pleural effusions, and supraventricular 
tachycardia late in the course of illness has been reported.41
Thrombotic complications seem to be the point of 
Figure 1. PRISMA flow diagram
Coronaviruses and the cardiovascular system
J Cardiovasc Thorac Res, 2021, 13(2), 92-101 95
Table 1. Included original studies in the manuscript
Coronavirus 
family 




Cardiovascular complications, No 
(percentage)




Guo et al.10 China, 2020
Retrospective, single 
center (187)
 Myocardial injury 52 (27.8%)
 VT/VF 11 (5.9%) 
NA
Patients with myocardial injury had:
More males 
Higher age





Wan et al.11 China, 2020
Retrospective, single 
center (135)
NA  Acute cardiac injury, 10 (7.4%)
Patients with higher CK MB:
 Were more severe case 
76
Huang et al.12 China, 2020
Prospective, 
multicenter (41) 
NA  Acute cardiac injury 5 (12%)
Patients with acute cardiac injury had:
 More need for ICU care.
83




 Acute cardiac injury, 33 (17%)
 Heart failure, 44 (23%)




Chen et al.14 China, 2020
Retrospective, single 
center (274)
 HscTnI >15.6 pg/mL, 83/203 
(41%)
 NT-proBNP ≥285 pg/mL, 
85/173 (49%)
 Acute cardiac injury, 72/94 (77%)
 Heart failure, 41/83 (49%)




Du et al.15 China, 2020
Retrospective, 
multicenter (85)
 CK>170U/L, 31 (36.5%)
 Acute cardiac injury, 38 (44.7%)
 Arrhythmia 51 (60%)
Cause of death:
 Cardiac arrest, 7/81 (8.64%) 
 Acute coronary syndrome, 4/81 (4.94%) 
 Malignant arrhythmia, 2/81 (2.47%)
69
Chen et al.15 China, 2020
Experimental study on 
human heart tissue, 
single center (45)
 SARS-CoV-2 might attack 
pericytes, and cause capillary 
endothelial cells dysfunction
NA NA 42




 CK ≥ 200 U/l, 90/657 (13.7 %) NA NA 85




 Increased serum CK, 4/60 
(6.7%)
NA NA 71




 Acute cardiac injury, 70 (21.0%)
 Arrhythmia, 35 (10.4 %)
 Cardiac insufficiency, 58 (17.4%)
Higher mortality was seen in patients with:
 Acute cardiac injury
 Arrhythmia
 Cardiac insufficiency 
83




 14 abnormal ECGs in cardiac 
injury patients: myocardial 
ischemia, T-wave depression 
and inversion, ST-segment 
depression, and Q waves. 
NA
Higher mortality was seen in patients with:
Cardiac injury.
More than half of the patients with cardiac 
injury experienced in-hospital death in this 
study, indicating that COVID-19–induced 
cardiac injury is associated with major 
adverse clinical outcomes.
88




 Elevated CK, 13 (13%) 
 One patient developed severe 
respiratory failure, heart failure, and 
sepsis. Expired due to sudden cardiac 
arrest on the 11th day of admission.
NA 69















Zheng et al.23 China. 2020
Retrospective, single 
center (161)
 CK ≥ 190 U/l, 17 (10.6 %) NA
Patients with high CK had more: 
 Severe disease
76
Han et al.24 China, 2020
Retrospective, single 
center (273)
 CK-MB > 5 ng/ml, 10 (3.66%)
Ultra-TnI > 0.04 ng/ml, 27 
(9.89%)
NT-proBNP >  900 pg/mL, 34 
(12.45%)
NA
Severity and case-fatality rate of COVID-19 
was associated with:
 Higher concentration of CK-MB
 Higher concentration of ultra-TnI 
 Higher concentration of NT-proBNP 
76
Yang et al.25 China, 2020
Retrospective, single 
center (92)
NA  Cardiac Injury, 31/91 (34.1%)
Cause of death:
 AMI, 6 (6.5%)
 Heart failure 2 (2.2%)
47
Deng et al.26 China, 2020
Retrospective single 
center (112)
 LVEF <50%, 6 (5.4%) 
 Possible myocarditis, 14 
(12.5%)
 Tachycardia, 33 (29.5%)
 ST segment elevation/ST-T 
changes, 22 (19.6%) 
 Ultra-TnI > 0.04 ng/ml, 42 
(37.5%)
 NA
 For all the patients who died during 
hospitalization, cardiac markers were 
elevated before death and cardiac troponin 
I was peaked within a week preceding 
death.
 Those with higher peak cardiac troponin 








 Acute cardiac injury, 11 (11.2%) Patients needing ICU care had more:
 Acute Cardiac injury 
69
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Coronavirus 
family 




Cardiovascular complications, No 
(percentage)










 RBBB in ECG, 7 (15.2%)
 Trace to mild mitral 
regurgitation, 17 (36.9%)
 Trace to mild aortic 
regurgitation, 2 (4.3%)
 Significantly higher left 
ventricular IMP at baseline vs 
day 30 (0.42 versus 0.33)
 Longer IVRT at baseline vs 
day 30 (102.9 versus 81.6ms)
 Lower FPV at baseline vs day 
30 (69.6 versus 83.8 cm/s)
 Lower doppler-derived CO at 
baseline vs day 30 (4.69 versus 
5.49 L/min)
 Lower Em at base line vs day 
30 (17.3 versus 19.3 cm/s) 
NA
Patients requiring mechanical ventilation 
had:
 Lower LVEF at baseline







 Palpitation, 5 (4%) 
 Elevated CK, 31 (26%) 
 No significant increase in 
troponin or CK-MB
 Tachycardia, 87 (71.9%) 
 Significant sinus bradycardia, 
18 (14.9%)
 Transient paroxysmal atrial fibrillation 
on day 8 hospitalisation, lasted for 
1 day and subsided spontaneously 
without treatment, 1 (0.82%)
 Significant hypotension during the 
hospitalisation period, 61 (50.4%)
 Cardiomegaly in first week of 
hospitalization, 8(6.6%)
 Cardiomegaly in second week of 
hospitalization, 7(5.8%),
 Cardiomegaly in third week of 
hospitalization, 4 (3.3%)
NA 85
Gu et al.30 China, 2005
Retrospective, multi 
center, (18)
 No obvious pathologic change 
in the heart. Lymphocytes and 
monocytes were found in some 
of these organs, mostly within 
vessels
NA NA 54




Abnormal CK, 43/109 (39%)
Abnormal CK, 64/118 (54%)
 Increased CK was significantly associated 
with poor outcome. 
71




 2 patients died because of AMI








 CK was not elevated 
significantly in confirmed SARS 
cases. 
 Post mortem analysis of 2 bodies 
revealed pulmonary thromboembolism as a 








 Elevated CK levels, 44 
(32.1%) 
NA
 None of the patients with elevated CK 
levels had abnormal values for CK-MB or 
troponin T, indicating that the source of CK 









 Ischemic stroke, 4 (2.01%)
 DVT, 11 (5.52%)
 Pulmonary embolism, 7 (3.51%)
Early Cause of death:
 DCM, 1 (0.50%)
 Cardiac failure with septicaemia shock, 1 
(0.50%)
 Ventricular fibrillation and end stage renal 
failure, 1 (0.50%)
Late (>7 days) cause of death:
AMI, 1 (0.50%)
83
Abbreviations: AMI, acute myocardial infarction; CK-MB, Creatine Kinase MB; CO, cardiac output; COVID-19, Coronavirus Disease 2019; DCM, dilated cardiomyopathy; DVT, deep 
vein thrombosis; ECG, electrocardiography; FPV, flow propagation velocity; HscTnI, high sensitivity troponin I; ICU, Intensive Care Unit; IMP, myocardial performance index; IVRT, 
Isovolumetric relaxation time; NA, not available; No, number; NT-proBNP, N-terminal pro-brain natriuretic peptide; RBBB, right bundle branch block; SARS-CoV-2, severe acute 
respiratory syndrome coronavirus 2; VF, ventricular fibrillation; VT, ventricular tachycardia
Table 1. Continues
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64 year-old female with 
hypertension and hyperlipidemia.
Persistent chest pressure for 
two days.
No remarkable sign on physical 
examination. 
Case 2:
38 year-old male with type 2 
diabetes mellitus. 
One week of cough, pleuritic 
chest pain and progressive 
shortness of breath.
Tachypnea on physical 
examination.
Case 3:
64 year-old female with non-
ischemic cardiomyopathy (recent 
normalization of LVEF), 
atrial fibrillation, hypertension and 
diabetes.
Non-productive cough and 
shortness 
of breath for two days.
Blood pressure 153/120 mmHg, 
heart rate 100 bpm, and oxygen 
saturation 88%.
Case 4:
A 51 year-old man with heart 
transplantation in 2007 and renal 
transplantation in 
2010.
Intermittent fever, dry cough, and 
shortness of breath for nine days.
Case 1: 
ECG: Sinus tachycardia at 102 bpm, low voltage QRS 
complexes in the limb leads, ST segment elevations 
in leads I, II, aVL, V2-V6 and 
PR elevation and ST depressions in aVR.
Laboratory: Troponin I on admission was 7.9 ng/mL.
Angiography: Non-obstructive coronary artery 
disease.




Laboratory: High sensitivity troponin T was 1341 ng/L.
TTE: Normal EF20-25%, with akinesis of the mid 
left ventricular segments, and normal right ventricular 
size with mildly reduced function during admission 
Case 3:
ECG: sinus rhythm, an isolated premature ventricular 
complex, premature atrial complexes, lateral T wave 
inversions and QTc 528 ms.
Laboratory: NT-proBNP 6,137 pg/mL, HscTnT 42 
ng/mL.
TTE: Severe LV systolic dysfunction. 
Bedside pulmonary artery catheterization revealed a 
right atrial pressure of 10 mmHg, pulmonary artery 
pressure 45/20 mmHg, with a Fick cardiac index of 
1.7 L/min/m2. 
Case 4:
ECG: Normal sinus rhythm with new nonspecific 
T-wave inversions in the inferior and lateral leads.
Laboratory: NT-proBNP 3212 pg/mL and HscTnT 
16 ng/L.
TTE: Normal cardiac allograft function.
Case 1:
On IABP and dobutamine infusion, her cardiac 
index and lactate normalized and her end-organ 
function remained stable. The troponin-I peaked 
at 18.6 ng/mL and subsequently trended down 
to 0.4 ng/mL. 
The IABP was weaned after 7 days and the 
patient remained hemodynamically stable off 
IABP and inotropes. On repeat echocardiography 
on hospital day 10, LVEF improved to 50% and 
wall thickness was reduced.
Case:2
He developed a supraventricular tachycardia and 
was successfully cardioverted. 
Developed acidosis and low o2 saturation. 
VV ECMO.
Vasopressor due to low blood pressure.
VAV ECMO.
Decannulated from ECMO after 7 days and is 
hemodynamically stable, although he remains on 
mechanical ventilation.
Case 3:
Respiratory status worsened rapidly, requiring 
intubation. She developed hypotension and was 
started on vasopressors. 
Dobutamine was started but was discontinued 
when she developed polymorphic ventricular 
tachycardia requiring cardioversion. IABP was 
considered but deferred due to improvement in 
the arterial lactate and blood pressure. Troponin 
levels remained relatively stable throughout (peak 
214 ng/mL). She remains intubated on day 9 of 
her hospitalization due to agitation with ventilator 
weaning attempts.
Case 4:
Following admission, the mycophenolate mofetil 
was discontinued. 
Through the first five days of the hospitalization, 
the patient was intermittently febrile and his 
inflammatory markers remained persistently 
elevated, though he remained clinically stable. He 







Chest pain and dyspnoea and 
diarrhoea for 3 days.
Blood pressure: 80/50 mmHg.
Chest x ray: Significant enlargement of the heart.
Chest CT: Pulmonary infection, enlarged heart, and 
pleural effusion.
ECG: ST-segment elevation acute inferior myocardial 
infarction.
CT coronary angiography: No coronary stenosis. 
Laboratory: Troponin T was more than 10 000ng/L. 
CK-MB 112.9ng/L. Natriuretic peptide BNP was up 
to 21 025ng/L. 







Symptoms improved significantly. One 
week later, normal heart size on chest x ray. 
Echocardiography showed that the size and 
function of the heart had returned to normal. 
Markers of myocardial injury dropped significantly 
after 1 week of treatment. 
After 3 weeks, the myocardial injury markers had 






A healthy 53-year-old woman.
Severe fatigue for 2 previous 
days. She denied chest pain, 
dyspnea, and further symptoms. 
She reported having fever and 
cough the week before.
Blood pressure of 90/50 mmHg, 
heart rate of 100 beats per 
minute, oxygen saturation of 98% 
while breathing ambient air, and 
body temperature of 36.6 °C.
ECG: Low voltage in the limb leads, minimal 
diffuse ST-segment elevation, and an ST-segment 
depression with T-wave inversion in lead V1 and aVR.
Chest x ray: Unremarkable.
Laboratory: Elevated high-sensitivity troponin T 
level of 0.24 ng/mL and CK–MB level of 20.3ng/mL, 
elevated NT-pro BNP levels (5647pg/mL).
TTE: RWMA with EF 40%.
Circumferential pericardial effusion that was 
most notable around the right cardiac chambers 
(maximum, 11mm) without signs of tamponade
Coronary angiography: No obstructive CAD.
CMR: Confirmed the increased wall thickness with 
diffuse biventricular hypokinesis, especially in the 
apical segments,and severe LV dysfunction (LVEF 
of 35%). T2-mapping sequences showed marked 
biventricular myocardial interstitial diffuse late 
gadolinium enhancement.
The myocardiale demand pattern of late gadolinium 
enhancement fulfilled all the Lake Louise criteria for 
the diagnosis of acute myocarditis.
Low BP.
Dobutamine.
TTE performed on day 6, revealed a significant 
reduction of LV wall thickness (interventricular 
septum, 11mm and posterior wall, 10mm), and 
improvement of LVEF to 44%, and a slight 
decrease of pericardial effusion (maximum, 
8-9mm). 
At the time of submission the patient was 
hospitalized with progressive clinical and 
hemodynamic improvement.
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Symptoms of fever, chills, cough, 
fatigue and shortness of breath.
Chest x-ray: showed multiple patchy shadows in 
both lungs.
Sudden Cardiac arrest on day 14. Died.
Biopsy of the heart showed a few interstitial 
mononuclear inflammatory infiltrates, but no other 








There was myocardial stromal oedema. The 
endothelial cells of small veins were swollen and 
the vascular walls were oedematous and infiltrated 
by monocytes and lymphocytes. There were focal 
hyaline degeneration and lysis of cardiac muscle 








4-day history of fluctuating 
fever up to 39∞C, dry cough 
with shortness of breath, and 
diarrhoea. 
ECG: New T-wave inversion in the precordial leads.
Laboratory: CK and cardiac troponin T levels were 
normal.
TTE: normal left ventricular function with no regional 
wall motion abnormalities or pericardial effusion. 
Chest x-ray: right middle zone ground-glass haziness
Angiography: normal coronary arteries. 
High-resolution CT scan (HRCT): presence of a 
pneumomediastinum.
Despite maximized medical treatment, she still 
complained of recurrent chest pain with reversible 
ECG changes of T-wave inversion in the 
precordial leads over the subsequent 6 days.
Her chest pain gradually subsided with analgesics 
and the ECG showed normalization of T-waves 










A 68-year-old woman, no risk 
factor with developed SARS
that was complicated by 






A 54-year-old female with 
dyslipidemia. 
Case 4: 
A 63-year-old man, with diabetes 
hypertension and IHD.
2 weeks after admission he 
developed partial hemispheric 
syndrome 
Case 5:
 A 39-year-old man complicated 
with AMI, and cardiac 
arrhythmias.
Case 1 : 
Brain CT: Infarctions in the left posterior and middle 
cerebral artery (PCA, MCA) territories. 
TTE: EF 30%.
Case 2:
ECG: T inversion on all electrocardiograph leads. 
TTE: normal ejection fraction and ventricular wall 
motion. No clots or vegetations were noted. 
Brain CT: massive right MCA infarction with oedema 
and early hydrocephalus. 
Case 3:
Brain CT: large infarctions in left PCA and bilateral 
MCA territories.
 No cardiac evaluation
Case 4:
Brain CT: left temporo-parietal infarction. 
TTE: Normal.
Case 5:
At autopsy: an infarction in the inferior lateral part of 
right occipital lobe was noted.
Sterile vegetations in multiple cardiac valves, deep 




Aspirin was started and LMWH discontinued.
She remains aphasic and hemiplegic.
IVIG for 16 days.
She was weaned off the ventilator two months 
later.
Case 2:
LMWH for 2 days.
Ventilation.
Died 1 week later.
Case 3:
 Her blood pressure dropped to systolic 60mmHg, 
but responded promptly to desmopression acetate 
(DDAVP), intravenous fluids and inotropic drugs.
LMWH.
IVIG.
Died 2 days later.
Case 4: 
No IVIG/No LMWH. Discharge
Case 5: 








Cases described in the study of 
Umapathiet al. 
Cases described in the study of Umapathiet al. 
20.5% had deep vein thrombosis, 11.4%, showed 
clinical evidence of pulmonary embolism, 15.9% 










A previously healthy 60-year-
old man.
4-day history of fever, shortness 
of breath, cough with yellowish 
sputum, and left side chest 
pain, which was worsened by 
inspiration.
Physical examination showed a 
body temperature of 38°C, blood 
pressure of 115/70 mm Hg, pulse 
rate of 120 beats per minute, and 
respiratory rate of 24 per minute. 
The jugular venous pressure was 
elevated.
Laboratory: elevated troponin-I level of 1.13 µg/L 
and an elevated pro-brain natriuretic peptide level of 
6000 pg/ml, which increased to 8906 pg/ml on the 
second day.
ECG: sinus tachycardia at a rate of 120 beats per 
minute and diffuse t-wave inversion. 
TTE: severe global LV systolic dysfunction and small 
pericardial effusion.
CMR: LGe in favor of myocarditis.
During the second week of admission, the patient 
required hemodialysis because of acute renal 
failure, which improved after 4 weeks. 
He also required intubation for mechanical 
ventilation because of respiratory failure that 
continued for 6 weeks. 
1 month rehabilitation.
LV systolic function remained severely impaired 
on echocardiography performed 3 months after 
the first one. He was discharged home when his 









Pericarditis, pericardial effusion, supraventricular 
tachycardia in one patient who died. 
Abbreviations: AMI, acute myocardial infarction; CK-MB, Creatine Kinase MB; CMR, cardiac magnetic resonance imaging; COVID-19, Coronavirus Disease 2019; CT, computed 
tomography; ECG, electrocardiography; HscTnT, high sensitivity troponin T; IABP, intra-aortic balloon pump; IHD, ischemic heart disease; IVIG, Intravenous immunoglobulin; LGe, 
late gadolinium enhancement; LMWH, low molecular weight heparin; LVEF, left ventricle ejection fraction; MCA, middle cerebral artery; MERS, middle east respiratory syndrome; No, 
number; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCA, posterior cerebral artery; RWMA, regional wall motion abnormality; SARS, severe acute respiratory syndrome; TTE, 
trans thoracic echocardiography; VAV, veno-arterial-venous; VV ECMO, veno-venous extracorporeal membrane oxygenation
* 124 interviews with 12 confirmed MERS infection
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similarity between the three Coronavirus infections; 
however, available data are limited in MERS compared 
to SARS and COVID-19. All forms of thrombotic 
complications including acute coronary syndromes, 
marantic valvular vegetations, deep vein thrombosis, 
pulmonary emboli, thrombosis in pulmonary veins, 
multi organ thrombosis, and thrombotic cerebrovascular 
accidents have been reported in both SARS and COVID-19. 
It is suggested that the thrombotic complications may be 
due to excessive inflammation, cytokine storm, platelet 
activation, endothelial dysfunction, and stasis. Also, the 
limited data in MERS suggests that the hematologic and 
coagulation disorders as the cause of the thrombotic 
complications in fatal cases.3,7,29,39,42,46,49-51
Conclusion
In this study we tried to show the similarities and 
differences between the three types of Coronavirus. At 
the beginning the COVID-19 pandemic, the lessons 
from other Coronavirus epidemics suggested that the 
infection can be more severe and even fatal in those with 
cardiovascular co morbidities and a trigger for acute 
coronary syndromes, thrombotic complications and 
heart failure exacerbations; however, COVID-19 seems 
to be able to induce new cardiovascular pathologies and 
cardiovascular complications and appears to be a serious 
threat in addition to respiratory problems. It should also 
be clarified whether the nature of novel Coronavirus 
2019 in terms of being more contagious and its spreading 
into different ethnicities and genetic backgrounds would 
be the cause of differences with its other ancestors. The 
long-term cardiovascular effects of COVID-19, along 
with the effect of future specific antiviral therapies are 
subject for further investigation. Further investigation is 
also needed to determine how patients with COVID-19 
related cardiovascular complications should be followed 
in the long-term. Is there a possibility of recurrence in 
cases of myocarditis caused by the COVID-19? Will 
asymptomatic patients, with mild symptoms and people 
who have just suffered from respiratory problems without 
cardiovascular involvement, be at greater risk for heart 
diseases in the future?
Ethical approval
The study was approved at the institutional research ethics 
committee with IR.RHC.REC.1399.005 ethical code.
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